Pfizer to Charge Nearly $1,400 for COVID-19 Drug Paxlovid

Pfizer projects Paxlovid sales to fall by 58 percent this year compared to 2022.
Pfizer to Charge Nearly $1,400 for COVID-19 Drug Paxlovid
A box of Paxlovid, Pfizer's COVID-19 pill. Jennifer Lorenzini/Reuters
Naveen Athrappully
Updated:
0:00

Pfizer plans to charge almost $1,400 for its COVID-19 antiviral drug Paxlovid, which comes at a time when the company is expecting lower sales of its COVID-19 products.

The five-day course of Paxlovid will be priced at $1,390 when it transitions to the commercial market, a Pfizer spokesperson told CNBC on Oct. 18. This is more than 2 1/2 times higher than the $529 price that the U.S. federal government paid for the drug. Since December 2021, the government has purchased Paxlovid and distributed it for free to the public. However, beginning next year, Pfizer will sell the drug directly to health insurers.

Naveen Athrappully
Naveen Athrappully
Author
Naveen Athrappully is a news reporter covering business and world events at The Epoch Times.
Related Topics